Gilead Sciences, Inc. (GILD) Stock Analysis
Range Bound setup · Temp Headwind edge
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $130.87, but acceptable to hold if already in. Reasons: Thin upside margin: 8.9%; Negative momentum.
Gilead Sciences is a biopharmaceutical company focused on HIV, liver diseases (hepatitis B/C), hematology/oncology, and inflammatory diseases. It earns revenue primarily through sales of branded antiviral therapies (Biktarvy, Veklury, Trodelvy) distributed via a concentrated... Read more
Hold if already holding. Not a fresh buy at $130.87, but acceptable to hold if already in. Reasons: Thin upside margin: 8.9%; Negative momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and news legal. Suitability: conservative.
Recent Developments — Gilead Sciences, Inc.
Latest news
- Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat — MarketBeat negative
- Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan — Stock Titan negative
- Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st — simplywall.st positive
- Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat — MarketBeat positive
- Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $130.87, but acceptable to hold if already in. Reasons: Thin upside margin: 8.9%; Negative momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $142.17 (+8.6%), stop $123.81 (−5.7%), A.R:R 1.7:1. Score 6.3/10, moderate confidence.
Take-profit target: $142.17 (+8.9% upside). Target $142.17 (+8.6%), stop $123.81 (−5.7%), A.R:R 1.7:1. Stop-loss: $123.81.
Thin upside margin: 8.9%; Negative momentum.
Gilead Sciences, Inc. trades at a P/E of 17.6 (forward 13.5). TrendMatrix value score: 6.3/10. Verdict: Hold.
39 analysts cover GILD with a consensus score of 4.1/5. Average price target: $158.
What does Gilead Sciences, Inc. do?Gilead Sciences is a biopharmaceutical company focused on HIV, liver diseases (hepatitis B/C), hematology/oncology, and...
Gilead Sciences is a biopharmaceutical company focused on HIV, liver diseases (hepatitis B/C), hematology/oncology, and inflammatory diseases. It earns revenue primarily through sales of branded antiviral therapies (Biktarvy, Veklury, Trodelvy) distributed via a concentrated wholesale channel in the U.S. and internationally.